mp.weixin.qq.com· 制药工艺与装备·· 6 hours agoPickScore68
Eli Lilly and METiS Therapeutics Strike $1.1 Billion Tissue-Specific LNP Platform Deal
礼来11亿美元押注，中国AI制药拿下首个平台级订单
In brief
On October 19, Eli Lilly and METiS Therapeutics entered a strategic collaboration worth $1.1 billion to jointly develop tissue-specific LNP delivery technology. The deal brings in METiS's foundational platform for de novo design of new lipid nanoparticles with generative AI, rather than any specific pipeline or single molecule. The material calls it China's first LNP delivery collaboration centered on a generative AI platform.
Why it matters
The deal is not tied to a pipeline but licenses a platform for AI de novo design of tissue-specific LNPs, a platform-style outbound deal structure.
Source: mp.weixin.qq.com · mp.weixin.qq.com